Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenjun Cheng

Showing results (111-120 of 163) with videos related to

Pageof 17
Sort By:
Genomics|June 1, 2020
Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironmentJinhui Liu, Sipei Nie, Zhipeng Wu, et al.
Cell Death & Disease|December 8, 2025
IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancerYeqing Zheng, Cheng Qian, Shuyi Zhang, et al.
Cancer Cell International|February 27, 2020
Identification of molecular markers associated with the progression and prognosis of endometrial cancer: a bioinformatic studyJinHui Liu, Mingming Feng, SiYue Li, et al.
Oncotargets and Therapy|December 11, 2019
Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6Mi Gong, Chengyan Luo, Huangyang Meng, et al.
Journal of Ovarian Research|September 3, 2021
CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancerSipei Nie, Yicong Wan, Hui Wang, et al.
Scientific Reports|October 22, 2024
Effectiveness and biocompatibility of a novel Schlemm's canal microstent for glaucoma managementManman Huang, Yu Zhang, Zhao Chen, et al.
Zhonghua Fu Chan Ke Za Zhi|October 21, 2014
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study]Yi Fu, Weifeng Mi, Lingzhi Li, et al.
Science Advances|April 15, 2026
Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivityHuangyang Meng, Qianjing Chang, Yashuang Zhang, et al.
International Journal of Biological Sciences|September 9, 2024
Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerJianqiang Liang, Xuan Zhou, Lin Yuan, et al.
Japanese Journal of Radiology|September 10, 2024
Multi-modality MRI radiomics phenotypes in intermediate-high risk endometrial cancer: correlations with histopathology and prognosisJiacheng Song, Xiaoting Jiang, Yao Lu, et al.
Pageof 17

Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Genomics|June 1, 2020
Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironmentJinhui Liu, Sipei Nie, Zhipeng Wu, et al.
Cell Death & Disease|December 8, 2025
IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancerYeqing Zheng, Cheng Qian, Shuyi Zhang, et al.
Cancer Cell International|February 27, 2020
Identification of molecular markers associated with the progression and prognosis of endometrial cancer: a bioinformatic studyJinHui Liu, Mingming Feng, SiYue Li, et al.
Oncotargets and Therapy|December 11, 2019
Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6Mi Gong, Chengyan Luo, Huangyang Meng, et al.
Journal of Ovarian Research|September 3, 2021
CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancerSipei Nie, Yicong Wan, Hui Wang, et al.
Scientific Reports|October 22, 2024
Effectiveness and biocompatibility of a novel Schlemm's canal microstent for glaucoma managementManman Huang, Yu Zhang, Zhao Chen, et al.
Zhonghua Fu Chan Ke Za Zhi|October 21, 2014
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study]Yi Fu, Weifeng Mi, Lingzhi Li, et al.
Science Advances|April 15, 2026
Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivityHuangyang Meng, Qianjing Chang, Yashuang Zhang, et al.
International Journal of Biological Sciences|September 9, 2024
Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerJianqiang Liang, Xuan Zhou, Lin Yuan, et al.
Japanese Journal of Radiology|September 10, 2024
Multi-modality MRI radiomics phenotypes in intermediate-high risk endometrial cancer: correlations with histopathology and prognosisJiacheng Song, Xiaoting Jiang, Yao Lu, et al.
Pageof 17